Luca Campedel

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Neoadjuvant Chemotherapy

Prognostic Factors

Radical Prostatectomy

Top Venues

Diagnostics (Basel, Switzerland)

Cancer medicine

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier, Yann-Alexandre Vano, Luca Campedel, Elshad Hasanov, Ziad Bakouny, Andrew W Hahn, Mehmet Asim Bilen, Pavlos Msaouel, Toni K Choueiri, Srinivas R Viswanathan, Kanishka Sircar, Laurence Albiges, Gabriel G Malouf, Nizar M Tannir
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. The oncologist (2023)
Paul Gougis, Baptiste Abbar, Julie Benzimra, Aurore Vozy, Jean-Philippe Spano, Luca Campedel
Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment. Diagnostics (Basel, Switzerland) 12 (8) (2022)
Sylvie Giacchetti, Lilith Faucheux, Charlotte Gardair, Caroline Cuvier, Anne de Roquancourt, Luca Campedel, David Groheux, Cedric de Bazelaire, Jacqueline Lehmann-Che, Catherine Miquel, Laurence Cahen Doidy, Malika Amellou, Isabelle Madelaine, Fabien Reyal, Laetitia Someil, Hamid Hocini, Christophe Hennequin, Luis Teixeira, Marc Espié, Sylvie Chevret, Vassili Soumelis, Anne Sophie Hamy
Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. Cancers 14 (5) (2022)
Anne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, Isabelle Peguillet, Marianne Gazzano, Maxime Descartes Mbogning Fonkou, Cassandra Thelemaque, Cedric Lebacle, Constance Thibault, Francois Audenet, Géraldine Pignot, Gwenaëlle Gravis, Carole Helissey, Luca Campedel, Morgan Roupret, Evanguelos Xylinas, Idir Ouzaid, Agathe Dubuisson, Marine Mazzenga, Caroline Flament, Pierre Ly, Virginie Marty, Nicolas Signolle, Allan Sauvat, Thomas Sbarrato, Mounia Filahi, Caroline Davin, Gabriel Haddad, Jacques Yb Khalil, Camille Blériot, François-Xavier Danlos, Garett Dunsmore, Kevin Mulder, Aymeric Silvin, Thibault Raoult, Baptiste Archambaud, Shaima Belhechmi, Ivo Gomperts Boneca, Nadège Cayet, Maryse Moya-Nilges, Adeline Mallet, Romain Daillère, Etienne Rouleau, Camelia Radulescu, Yves Allory, Jacques Fieschi, Mathieu Rouanne, Florent Ginhoux, Gwénaël Le Teuff, Lisa Derosa, Aurélien Marabelle, Jeroen van Dorp, Nick van Dijk, Michiel S Van Der Heijden, Benjamin Besse, Fabrice Andre, Miriam Merad, Guido Kroemer, Jean Yves Scoazec, Laurence Zitvogel, Yohann Loriot
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. Cancer discovery 12 (10) (2022)
Matthieu Delaye, Adrien Rousseau, Mélanie Try, Christophe Massard, Luca Campedel, Marc Hilmi, Corinne Bagnis
Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer. Cancer medicine (2022)
Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu Roulleaux Dugage, Stephane Marie Oudard, Constance Thibault
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. Cancers 14 (7) (2022)
Luca Campedel, Paul Blanc-Durand, Asker Bin Asker, Jacqueline Lehmann-Che, Caroline Cuvier, Cedric De Bazelaire, Luis Teixeira, Stephanie Becourt, Florence Ledoux, Hamid Hocini, Edwige Bourstyn, Catherine Miquel, Sophie Guillerm, Patrick Charveriat, Marc Espié, Anne De Roquancourt, Anne Sophie Hamy, Sylvie Giacchetti
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC. Cancers 12 (9) (2020)